Cybin is a clinical-stage biopharmaceutical enterprise that formally adopted Helus Pharma as its primary commercial operating name. The company focuses intensely on developing proprietary novel serotonergic agonists designed to target specific neurological pathways and promote neuroplasticity for the treatment of severe psychiatric disorders. Its advanced therapeutic pipeline targets significant unmet medical needs in conditions such as major depressive disorder and generalized anxiety disorder. By leveraging advanced drug delivery technologies and conducting rigorous clinical trials across international research sites, the enterprise aims to transform the mental health treatment landscape through innovative pharmaceutical solutions.